Products Pegaptanib was commercially available as a solution for injection (Macugen). It was approved in many countries in 2006 and has since been discontinued. Structure and properties Pegaptanib is an aptamer and a pegylated and modified oligonucleotide. Effects Pegaptanib (ATC S01LA03) binds to extracellular vascular endothelial growth factor (VEGF) and inhibits its activity. VEGF plays … Pegaptanib
Products Bevacizumab is commercially available as a concentrate for the preparation of an infusion solution (Avastin). It was approved in many countries and in the United States in 2004 and in the EU in 2005. Biosimilars have been approved in some countries and also in many countries. Structure and properties Bevacizumab is a recombinant, humanized … Bevacizumab
Products Ranibizumab is commercially available as a solution for injection (Lucentis). The drug was approved in the United States and many countries in 2006 and in the EU in 2007. The drug’s high price is controversial, especially when compared with bevacizumab (Avastin), which is structurally and pharmacologically similar. Bevacizumab is not approved for these indications … Ranibizumab
Products Aflibercept is marketed as an injectable (Eylea). It was approved in many countries in 2012. Structure and properties Aflibercept (C4318H6788N1164O1304S32) is a recombinant fusion protein consisting of the extracellular portions of human VEGF receptor 1 and 2 coupled to the Fc receptor of human IgG1. Effects Aflibercept (ATC S01LA05) binds the growth factors VEGF-A … Aflibercept
